Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

100180

	registered interest
	date	21/10/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	NHS England
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, how many meetings the Parliamentary Under-Secretary of State for Public Health has had with James Palmer, Clinical Director for Specialised Commissioning at NHS England since 1 April 2014.
	tabling member constituency	Wells
	tabling member printed	Tessa Munt
	uin	211213
	answer	answer is ministerial correction date of answer 28/10/2014 answer text <p>I have had no meetings with James Palmer, Clinical Director for Specialised Commissioning at NHS England since 1 April 2014.</p><p> </p><p><strong> </strong></p><p> </p><p>There is regular contact between Departmental officials and Clinical Directors at NHS England, including the Clinical Director for Specialised Commissioning.</p><p> </p><p><strong> </strong></p><p> </p> answering member constituency Battersea answering member printed Jane Ellison question first answered 28/10/2014 17:45:28 answering member 3918 label Biography information for Jane Ellison
	tabling member	4089 label Biography information for Tessa Munt

100181

	registered interest
	date	21/10/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	NHS England
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, how many meetings he has had with Simon Stevens, Chief Executive of NHS England since 1 April 2014.
	tabling member constituency	Wells
	tabling member printed	Tessa Munt
	uin	211214
	answer	answer is ministerial correction date of answer 28/10/2014 answer text <p>My Rt. hon. Friend, the Secretary of State, meets with Mr Stevens on a weekly basis with additional meetings arranged as and when required, which often include other members of the Ministerial team.</p><p> </p> answering member constituency Central Suffolk and North Ipswich answering member printed Dr Daniel Poulter question first answered 28/10/2014 15:31:37 answering member 3932 label Biography information for Dr Dan Poulter
	tabling member	4089 label Biography information for Tessa Munt

100196

	registered interest
	date	21/10/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Radiotherapy
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, whether the signature authorising Individual Funding Requests made to NHS England for Gamma Knife treatment by University College Hospital London, Queen Square, is that of a senior clinician employed by University College Hospital London.
	tabling member constituency	Wells
	tabling member printed	Tessa Munt
	uin	211310
	answer	answer is ministerial correction date of answer 27/10/2014 answer text <p>We are advised by NHS England that the clinician who authorises Individual Funding Requests for Gamma Knife treatment to be undertaken at the Queens Square Radiology Centre Ltd (QSRC) is a surgeon at the National Hospital for Neurosurgery and Neurology (NHNN), part of University College London Hospitals NHS Foundation Trust (UCLH).</p><p> </p><p> </p><p> </p><p>Gamma Knife treatment is not undertaken by UCLH but by the private company QSRC, which is based at NHNN but has no formal relationship with UCLH.</p><p> </p><p><strong> </strong></p><p> </p> answering member constituency Battersea answering member printed Jane Ellison question first answered 27/10/2014 16:54:23 answering member 3918 label Biography information for Jane Ellison
	tabling member	4089 label Biography information for Tessa Munt

102048

	registered interest
	date	31/10/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Radiotherapy
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, with reference to the Answer of 22 October 2013, to Question 171517, for what reasons NHS England's review into stereotactic radiosurgery was not completed by the end of 2013; and when NHS England will complete this review.
	tabling member constituency	Wells
	tabling member printed	Tessa Munt
	uin	212823
	answer	answer is ministerial correction date of answer 07/11/2014 answer text <p>NHS England released ‘Stereotactic Radiosurgery and Radiotherapy Services – needs assessment and service review’ on 3 November. NHS England is now consulting on this document until 26 January 2015, after which it will publish a report outlining the key themes of the consultation findings on its website.</p><p> </p><p> </p><p> </p><p>NHS England advises us that the review took more time than originally planned to ensure that the options being consulted on were as comprehensive as possible. This included further testing of a number of issues including the appropriate level of throughput activity in each centre.</p><p> </p><p> </p><p> </p> answering member constituency Battersea answering member printed Jane Ellison question first answered 07/11/2014 13:36:47 answering member 3918 label Biography information for Jane Ellison
	tabling member	4089 label Biography information for Tessa Munt

102052

	registered interest
	date	31/10/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	University College Hospital
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, whether University College Hospital London included the provision of gamma knife services at its Queen Square site in its notification log to commissioners before 1 April 2013.
	tabling member constituency	Wells
	tabling member printed	Tessa Munt
	uin	212820
	answer	answer is ministerial correction date of answer 07/11/2014 answer text <p>The Consolidated Notification Log 2012/13 record dated 30 September 2011 makes reference to a gamma knife service that might be available sometime in the future at the National Hospital for Neurology and Neurosurgery, part of University College London Hospitals NHS Foundation Trust (UCLH). A gamma knife service is not currently provided by the Trust.</p><p> </p><p> </p><p> </p><p>A gamma knife service is provided by an independent provider called Queen’s Square Radiotherapy Centre Limited based at Queen’s Square (a site owned by UCLH).</p><p> </p> answering member constituency Battersea answering member printed Jane Ellison question first answered 07/11/2014 13:35:45 answering member 3918 label Biography information for Jane Ellison
	tabling member	4089 label Biography information for Tessa Munt

106317

	registered interest
	date	04/11/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Cancer Drugs Fund
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, with reference to NHS England's consultation document Proposal for a sustainable Cancer Drug Fund, page 9, Points 24 and 25, what NHS England's overspend of the Cancer Drug Fund (CDF) was during its first year in charge of the CDF; whether the CDF was in budget each year prior to 1 April 2013; how much was taken from the radiotherapy budget to underwrite the overspend; from which disease area money was taken to underwrite the CDF overspend; and how much funding was taken in such a fashion to underwrite the overspend.
	tabling member constituency	Wells
	tabling member printed	Tessa Munt
	uin	213358
	answer	answer is ministerial correction date of answer 07/11/2014 answer text <p><strong> </strong></p><p> </p><p>Prior to April 2013, the Cancer Drugs Fund was administered through clinical panels based in each strategic health authority. There were no overspends through the Fund during this period.</p><p> </p><p> </p><p> </p><p>NHS England has had oversight of the Cancer Drugs Fund since April 2013 and publishes information on spend and patient numbers routinely on its website at:</p><p> </p><p> </p><p> </p><p><a href="http://www.england.nhs.uk/ourwork/pe/cdf/" target="_blank">www.england.nhs.uk/ourwork/pe/cdf/</a></p><p> </p><p> </p><p> </p><p>NHS England has published a summary financial report for the Cancer Drugs Fund which states that the Fund was overspent by £30,539,000 in 2013-14. We understand from NHS England that this overspend was not funded from funding for radiotherapy services but from underspends in other parts of NHS England’s budget.</p><p> </p><p> </p><p> </p><p>Since October 2010, over 55,000 patients in England have benefitted from the Cancer Drugs Fund.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 07/11/2014 14:49:39 answering member 4020 label Biography information for George Freeman
	tabling member	4089 label Biography information for Tessa Munt

106319

	registered interest
	date	04/11/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Radiotherapy
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, whether NHS England's Stereotactic Radiosurgery and Radiotherapy Services Needs Assessment and Service Review published in November 2014 is solely for the purpose of assessing the needs of intracranial radiotherapy treatment in England.
	tabling member constituency	Wells
	tabling member printed	Tessa Munt
	uin	213359
	answer	answer is ministerial correction date of answer 07/11/2014 answer text <p>NHS England’s review is concerned with assessing and meeting the need for the treatment of intracranial conditions with SRS/SRT; fractionated extracranial radiotherapy and Stereotactic Ablative Radiotherapy (SABR) are not included in the review.</p><p> </p><p><strong> </strong></p><p> </p><p>The two activity scenarios in the consultation document assume a significant growth in treatment rates. Scenario A is based on the level of need identified in the NHS England Clinical Commissioning Policies, whilst scenario B is based on an expected growth demand based on the treatment rates of some other European countries. The relative merits of these two scenarios are laid out from page eight of the consultation document</p><p> </p><p> </p><p> </p><p>www.engage.england.nhs.uk/survey/options-for-change/supporting_documents/srssrtconsultguide021114.pdf</p><p> </p><p> </p><p> </p><p>NHS England’s reasons for recommending scenario A with a seven-day working week, ‘Option 2’, is set out in their report as follows:</p><p> </p><p> </p><p> </p><p>“SCOG [the Specialised Commissioning Oversight Group] decided on Option 2 as the preferred option as it is based on seven-day working, which aligns to the national strategic direction of moving towards seven-day service provision. Additionally, the risk of overcapacity is minimised if clinical trends change more slowly than expected because the centres providing the service could revert to fewer days per week. The avoidance of machines lying idle 2/7ths of the week will ensure best price for the NHS. Option 2 could be superseded by further expansion of national capacity should the activity levels increase beyond those described in Scenario A.”</p><p> </p><p> </p><p> </p><p>“It was recognised that in planning for Option 2, future increases in capacity would still be possible should activity levels rise beyond those described in Scenario A, in order to mitigate any risk of future under-capacity”</p><p> </p><p> </p><p> </p><p>The national recommendation that a minimum number patients be treated each year relates specifically to Stereotactic Ablative Radiotherapy (SABR) which is out of the scope of this consultation.</p><p> </p><p> </p><p> </p><p>NHS England's Stereotactic Radiosurgery and Radiotherapy Services Needs Assessment and Service Review is currently subject to an ongoing public consultation, which closes on 26 January 2015. NHS England would welcome any detailed comments being fed directly into the consultation process, including on data sources. Comments can be made at this link:</p><p> </p><p> </p><p>www.engage.england.nhs.uk/survey/options-for-change</p> answering member constituency Battersea answering member printed Jane Ellison grouped question UIN 213360 213361 213362 question first answered 07/11/2014 13:57:03 answering member 3918 label Biography information for Jane Ellison
	tabling member	4089 label Biography information for Tessa Munt

106320

	registered interest
	date	04/11/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Brain: Tumours
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, with reference to NHS England's Stereotactic Radiosurgery and Radiotherapy Services Needs Assessment and Service Review published in November 2014, what evidence NHS England has received that demonstrates that instances of both malignant and benign brain tumours are lower in England than in other devoloped countries; and for what reasons NHS England is supporting proposals which will prevent the NHS from adopting a programme to allow it to reach parity with other developed countries for the provision of stereotactic radiotherapy for brain tumours.
	tabling member constituency	Wells
	tabling member printed	Tessa Munt
	uin	213360
	answer	answer is ministerial correction date of answer 07/11/2014 answer text <p>NHS England’s review is concerned with assessing and meeting the need for the treatment of intracranial conditions with SRS/SRT; fractionated extracranial radiotherapy and Stereotactic Ablative Radiotherapy (SABR) are not included in the review.</p><p> </p><p><strong> </strong></p><p> </p><p>The two activity scenarios in the consultation document assume a significant growth in treatment rates. Scenario A is based on the level of need identified in the NHS England Clinical Commissioning Policies, whilst scenario B is based on an expected growth demand based on the treatment rates of some other European countries. The relative merits of these two scenarios are laid out from page eight of the consultation document</p><p> </p><p> </p><p> </p><p>www.engage.england.nhs.uk/survey/options-for-change/supporting_documents/srssrtconsultguide021114.pdf</p><p> </p><p> </p><p> </p><p>NHS England’s reasons for recommending scenario A with a seven-day working week, ‘Option 2’, is set out in their report as follows:</p><p> </p><p> </p><p> </p><p>“SCOG [the Specialised Commissioning Oversight Group] decided on Option 2 as the preferred option as it is based on seven-day working, which aligns to the national strategic direction of moving towards seven-day service provision. Additionally, the risk of overcapacity is minimised if clinical trends change more slowly than expected because the centres providing the service could revert to fewer days per week. The avoidance of machines lying idle 2/7ths of the week will ensure best price for the NHS. Option 2 could be superseded by further expansion of national capacity should the activity levels increase beyond those described in Scenario A.”</p><p> </p><p> </p><p> </p><p>“It was recognised that in planning for Option 2, future increases in capacity would still be possible should activity levels rise beyond those described in Scenario A, in order to mitigate any risk of future under-capacity”</p><p> </p><p> </p><p> </p><p>The national recommendation that a minimum number patients be treated each year relates specifically to Stereotactic Ablative Radiotherapy (SABR) which is out of the scope of this consultation.</p><p> </p><p> </p><p> </p><p>NHS England's Stereotactic Radiosurgery and Radiotherapy Services Needs Assessment and Service Review is currently subject to an ongoing public consultation, which closes on 26 January 2015. NHS England would welcome any detailed comments being fed directly into the consultation process, including on data sources. Comments can be made at this link:</p><p> </p><p> </p><p>www.engage.england.nhs.uk/survey/options-for-change</p> answering member constituency Battersea answering member printed Jane Ellison grouped question UIN 213359 213361 213362 question first answered 07/11/2014 13:57:04 answering member 3918 label Biography information for Jane Ellison
	tabling member	4089 label Biography information for Tessa Munt

106321

	registered interest
	date	04/11/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Radiotherapy
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, with reference to NHS England's Stereotactic Radiosurgery and Radiotherapy Services Needs Assessment and Service Review published in November 2014, section 58, how NHS England is able accurately to protect the growth requirements for stereotactic radiosurgery if the data source it is using does not allow it to draw firm conclusions for the purposes of this Review.
	tabling member constituency	Wells
	tabling member printed	Tessa Munt
	uin	213361
	answer	answer is ministerial correction date of answer 07/11/2014 answer text <p>NHS England’s review is concerned with assessing and meeting the need for the treatment of intracranial conditions with SRS/SRT; fractionated extracranial radiotherapy and Stereotactic Ablative Radiotherapy (SABR) are not included in the review.</p><p> </p><p><strong> </strong></p><p> </p><p>The two activity scenarios in the consultation document assume a significant growth in treatment rates. Scenario A is based on the level of need identified in the NHS England Clinical Commissioning Policies, whilst scenario B is based on an expected growth demand based on the treatment rates of some other European countries. The relative merits of these two scenarios are laid out from page eight of the consultation document</p><p> </p><p> </p><p> </p><p>www.engage.england.nhs.uk/survey/options-for-change/supporting_documents/srssrtconsultguide021114.pdf</p><p> </p><p> </p><p> </p><p>NHS England’s reasons for recommending scenario A with a seven-day working week, ‘Option 2’, is set out in their report as follows:</p><p> </p><p> </p><p> </p><p>“SCOG [the Specialised Commissioning Oversight Group] decided on Option 2 as the preferred option as it is based on seven-day working, which aligns to the national strategic direction of moving towards seven-day service provision. Additionally, the risk of overcapacity is minimised if clinical trends change more slowly than expected because the centres providing the service could revert to fewer days per week. The avoidance of machines lying idle 2/7ths of the week will ensure best price for the NHS. Option 2 could be superseded by further expansion of national capacity should the activity levels increase beyond those described in Scenario A.”</p><p> </p><p> </p><p> </p><p>“It was recognised that in planning for Option 2, future increases in capacity would still be possible should activity levels rise beyond those described in Scenario A, in order to mitigate any risk of future under-capacity”</p><p> </p><p> </p><p> </p><p>The national recommendation that a minimum number patients be treated each year relates specifically to Stereotactic Ablative Radiotherapy (SABR) which is out of the scope of this consultation.</p><p> </p><p> </p><p> </p><p>NHS England's Stereotactic Radiosurgery and Radiotherapy Services Needs Assessment and Service Review is currently subject to an ongoing public consultation, which closes on 26 January 2015. NHS England would welcome any detailed comments being fed directly into the consultation process, including on data sources. Comments can be made at this link:</p><p> </p><p> </p><p>www.engage.england.nhs.uk/survey/options-for-change</p> answering member constituency Battersea answering member printed Jane Ellison grouped question UIN 213359 213360 213362 question first answered 07/11/2014 13:57:04 answering member 3918 label Biography information for Jane Ellison
	tabling member	4089 label Biography information for Tessa Munt

106322

	registered interest
	date	04/11/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Radiotherapy
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, with reference to NHS England's Stereotactic Radiosurgery and Radiotherapy Services Needs Assessment and Service Review published in November 2014, section 96, if he will ensure that NHS England's proposals to use modified Linacs to supplement highly specialised stereotactic radiotherapy provision (a) comply with national recommendations that a minimum number of 25 patients is treated each year and (b) do not reduce patient access to the conventional radiotherapy the Linacs are designed to provide.
	tabling member constituency	Wells
	tabling member printed	Tessa Munt
	uin	213362
	answer	answer is ministerial correction date of answer 07/11/2014 answer text <p>NHS England’s review is concerned with assessing and meeting the need for the treatment of intracranial conditions with SRS/SRT; fractionated extracranial radiotherapy and Stereotactic Ablative Radiotherapy (SABR) are not included in the review.</p><p> </p><p><strong> </strong></p><p> </p><p>The two activity scenarios in the consultation document assume a significant growth in treatment rates. Scenario A is based on the level of need identified in the NHS England Clinical Commissioning Policies, whilst scenario B is based on an expected growth demand based on the treatment rates of some other European countries. The relative merits of these two scenarios are laid out from page eight of the consultation document</p><p> </p><p> </p><p> </p><p>www.engage.england.nhs.uk/survey/options-for-change/supporting_documents/srssrtconsultguide021114.pdf</p><p> </p><p> </p><p> </p><p>NHS England’s reasons for recommending scenario A with a seven-day working week, ‘Option 2’, is set out in their report as follows:</p><p> </p><p> </p><p> </p><p>“SCOG [the Specialised Commissioning Oversight Group] decided on Option 2 as the preferred option as it is based on seven-day working, which aligns to the national strategic direction of moving towards seven-day service provision. Additionally, the risk of overcapacity is minimised if clinical trends change more slowly than expected because the centres providing the service could revert to fewer days per week. The avoidance of machines lying idle 2/7ths of the week will ensure best price for the NHS. Option 2 could be superseded by further expansion of national capacity should the activity levels increase beyond those described in Scenario A.”</p><p> </p><p> </p><p> </p><p>“It was recognised that in planning for Option 2, future increases in capacity would still be possible should activity levels rise beyond those described in Scenario A, in order to mitigate any risk of future under-capacity”</p><p> </p><p> </p><p> </p><p>The national recommendation that a minimum number patients be treated each year relates specifically to Stereotactic Ablative Radiotherapy (SABR) which is out of the scope of this consultation.</p><p> </p><p> </p><p> </p><p>NHS England's Stereotactic Radiosurgery and Radiotherapy Services Needs Assessment and Service Review is currently subject to an ongoing public consultation, which closes on 26 January 2015. NHS England would welcome any detailed comments being fed directly into the consultation process, including on data sources. Comments can be made at this link:</p><p> </p><p> </p><p>www.engage.england.nhs.uk/survey/options-for-change</p> answering member constituency Battersea answering member printed Jane Ellison grouped question UIN 213359 213360 213361 question first answered 07/11/2014 13:57:04 answering member 3918 label Biography information for Jane Ellison
	tabling member	4089 label Biography information for Tessa Munt